11:08 AM EST, 01/10/2025 (MT Newswires) -- Y-mAbs Therapeutics ( YMAB ) said Friday it is realigning its internal operations and establishing radiopharmaceuticals and Danyelza units.

The company expects a reduction in its current staffing of up to about 13%, and plans to transfer some jobs to the US from Denmark to better coordinate the advancement of its radiopharmaceutical platform and to make a small adjustment in the Danyelza commercial team.

Y-mAbs also reported preliminary full-year 2024 total net revenue of about $88 million, compared with its previously provided range of $87 million to $95 million. Analysts polled by FactSet expect $88.2 million.

Shares of the company were down by nearly 6% in recent Friday trading.

Price: 7.01, Change: -0.38, Percent Change: -5.14